dc.contributor.author
Moisoiu, Tudor
dc.contributor.author
Dragomir, Mihnea P.
dc.contributor.author
Iancu, Stefania D.
dc.contributor.author
Schallenberg, Simon
dc.contributor.author
Birolo, Giovanni
dc.contributor.author
Ferrero, Giulio
dc.contributor.author
Burghelea, Dan
dc.contributor.author
Stefancu, Andrei
dc.contributor.author
Cozan, Ramona G.
dc.contributor.author
Licarete, Emilia
dc.contributor.author
Allione, Alessandra
dc.contributor.author
Matullo, Giuseppe
dc.contributor.author
Iacob, Gheorghita
dc.contributor.author
Bálint, Zoltán
dc.contributor.author
Badea, Radu I.
dc.contributor.author
Naccarati, Alessio
dc.contributor.author
Horst, David
dc.contributor.author
Pardini, Barbara
dc.contributor.author
Leopold, Nicolae
dc.contributor.author
Elec, Florin
dc.date.accessioned
2024-01-24T14:43:31Z
dc.date.available
2024-01-24T14:43:31Z
dc.identifier.uri
https://refubium.fu-berlin.de/handle/fub188/42204
dc.identifier.uri
http://dx.doi.org/10.17169/refubium-41929
dc.description.abstract
Background: Bladder cancer (BC) has the highest per-patient cost of all cancer types. Hence, we aim to develop a non-invasive, point-of-care tool for the diagnostic and molecular stratification of patients with BC based on combined microRNAs (miRNAs) and surface-enhanced Raman spectroscopy (SERS) profiling of urine.
Methods: Next-generation sequencing of the whole miRNome and SERS profiling were performed on urine samples collected from 15 patients with BC and 16 control subjects (CTRLs). A retrospective cohort (BC = 66 and CTRL = 50) and RT-qPCR were used to confirm the selected differently expressed miRNAs. Diagnostic accuracy was assessed using machine learning algorithms (logistic regression, naive Bayes, and random forest), which were trained to discriminate between BC and CTRL, using as input either miRNAs, SERS, or both. The molecular stratification of BC based on miRNA and SERS profiling was performed to discriminate between high-grade and low-grade tumors and between luminal and basal types.
Results: Combining SERS data with three differentially expressed miRNAs (miR-34a-5p, miR-205-3p, miR-210-3p) yielded an Area Under the Curve (AUC) of 0.92 +/- 0.06 in discriminating between BC and CTRL, an accuracy which was superior either to miRNAs (AUC = 0.84 +/- 0.03) or SERS data (AUC = 0.84 +/- 0.05) individually. When evaluating the classification accuracy for luminal and basal BC, the combination of miRNAs and SERS profiling averaged an AUC of 0.95 +/- 0.03 across the three machine learning algorithms, again better than miRNA (AUC = 0.89 +/- 0.04) or SERS (AUC = 0.92 +/- 0.05) individually, although SERS alone performed better in terms of classification accuracy.
Conclusion: miRNA profiling synergizes with SERS profiling for point-of-care diagnostic and molecular stratification of BC. By combining the two liquid biopsy methods, a clinically relevant tool that can aid BC patients is envisaged.
en
dc.rights.uri
https://creativecommons.org/licenses/by/4.0/
dc.subject
Bladder cancer
en
dc.subject
Liquid biopsy
en
dc.subject
Molecular subtypes
en
dc.subject.ddc
600 Technik, Medizin, angewandte Wissenschaften::610 Medizin und Gesundheit::610 Medizin und Gesundheit
dc.title
Combined miRNA and SERS urine liquid biopsy for the point-of-care diagnosis and molecular stratification of bladder cancer
dc.type
Wissenschaftlicher Artikel
dcterms.bibliographicCitation.articlenumber
39
dcterms.bibliographicCitation.doi
10.1186/s10020-022-00462-z
dcterms.bibliographicCitation.journaltitle
Molecular Medicine
dcterms.bibliographicCitation.number
1
dcterms.bibliographicCitation.originalpublishername
Springer Nature
dcterms.bibliographicCitation.volume
28
refubium.affiliation
Charité - Universitätsmedizin Berlin
refubium.funding
Springer Nature DEAL
refubium.resourceType.isindependentpub
no
dcterms.accessRights.openaire
open access
dcterms.bibliographicCitation.pmid
35365098
dcterms.isPartOf.issn
1076-1551
dcterms.isPartOf.eissn
1528-3658